Michael Burkes Brophy has filed a notice to sell 1,178 shares of Natera, Inc., a significant transaction valued at approximately $483,946. This filing, dated October 28, 2026, indicates Brophy's ongoing engagement with the company's stock and reflects broader trading activity in the medical laboratories sector.

Natera, Inc. is a company operating within the medical laboratories sector, as indicated by its Standard Industrial Classification (SIC) code. The company is based in Austin, Texas, and is known for its focus on genetic testing and diagnostics.

The filing reveals that Brophy acquired these shares through Restricted Stock Units and plans to sell them on the NASDAQ exchange. The aggregate market value of the shares is reported to be $483,945.96. The filing also notes that Brophy sold 771 shares on October 27, 2026, for gross proceeds of $312,177.90.

This transaction may affect Natera, Inc.'s stock performance and investor sentiment, particularly as it highlights the trading activities of its officers. Brophy's previous sales include transactions on July 29 and August 4, 2026, indicating a pattern of selling shares.

Details were not available in the SEC filing regarding any future plans or additional transactions.

According to the filing, Michael Burkes Brophy's recent acquisition of the 1,178 shares occurred on October 26, 2026, through Restricted Stock Units granted by the issuer, Natera, Inc. This transaction indicates Brophy's continued investment in the company, which is incorporated in Delaware and has a fiscal year ending on December 31.

The filing also notes that Brophy's recent sales activity includes a total of 2,429 shares sold in the past three months, with gross proceeds amounting to $1,003,824.61. This includes the sale of 1,863 shares on July 29, 2026, for $464,594.94, and 317 shares on July 31, 2026, for $84,952.61. Notably, some of these transactions were executed under a 10b5-1 Sales Plan adopted on September 10, 2025, which allows for planned sales of stock to mitigate insider trading concerns.

The filing does not provide information on Brophy's total holdings in Natera, Inc. following the recent sales or any potential future transactions beyond the current notice. Additionally, there are no details regarding the reasons behind the sales or the strategic implications for Brophy's role within the company.